The Ottawa Hospital
Ottawa, Ontario, K1H 8L6, Canada
NCT Number: NCT03422120
Natural killer (NK) cells are leukocytes of the innate immune system and play a central role in the control of cancer metastases. NK cells and other innate immune cells often do not function well in patients with cancer and are also profoundly suppressed after cancer surgery. Dr. Auer's Lab and others have shown that NK cells are critically important in the clearance of tumor metastases and that their impairment can be recovered with immune therapy augmenting the innate immune system. Several studies suggest that cancer patients have depressed NK cell cytotoxicity as compared to healthy controls but that following resection of the cancer, NK cell cytotoxicity returns to normal levels. In this observational study, the investigators will measure NK cell cytotoxicity by the gold standard method (51Cr, a chromium51 release assay) and by a new interferon-ɣ (IFN-ɣ) based assay (NK-Vue™) in healthy humans and colorectal cancer (CRC) surgery patients seen a The Ottawa Hospital. The results of this study will determine if the NK-Vue™ is able to discriminate between healthy human volunteers and newly diagnosed cancer patients and is sufficiently sensitive to detect transient NK cell suppression immediately following surgery.
Looking for future studies?
Notify Me40 year and older
All sexes
Observational
Ottawa, Ontario, K1H 8L6, Canada
Rationale:
The purpose of this program is to obtain consent for and to outline the process for collection of fresh blood sample from healthy humans and colorectal cancer patients before and after surgical resection.
Procurement of fresh human blood is required for the following:
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Subjects had a blood test to measure NK cell activity (NKA) at different time points
Other names: NK-Vue
Time frame: baseline vs. Postoeprative Day (POD) 1
Measure of NK cell IFN-gamma secretion
Time frame: baseline
Measure of NK cell IFN-gamma secretion
Ottawa Hospital Research Institute
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03598413
Atrophy, Colonic Diseases
Guildford, Surrey, United Kingdom
View Trial DetailsNCT00911391
Colectomy, Colonic Diseases
Auckland, New Zealand
View Trial DetailsNCT07725692
Anastomotic Leak, Colon Cancer
Alexandria, Please Select, Egypt
View Trial DetailsNCT06866678
Colonic Diseases, Colorectal Cancer
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial Details